AbbVie vs Johnson & Johnson stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
AbbVie grows faster. Johnson & Johnson is more profitable, is cheaper for its profits and has less debt.
Side by side
| AbbVie | Johnson & Johnson | |
|---|---|---|
| $506 billion | $651 billion | |
| 6.9% | 28.5% | |
| +6.0% | +2.7% | |
| 119.7× | 24.3× | |
| 3.5 years | 0.7 years | |
| 12.0% | 21.0% | |
| 3.1% | 2.3% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: AbbVie vs Eli Lilly · AbbVie vs McKesson · AbbVie vs Medtronic · AbbVie vs Merck & · Johnson & Johnson vs Abbott Laboratories · Johnson & Johnson vs Amgen · Johnson & Johnson vs argenx · Johnson & Johnson vs AstraZeneca

